Efficacy of azilsartan medoxomil with chlorthalidone in hypertension

References

• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 2014;16:14-26
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure; meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9(9 Suppl):2-6
   PubMedGoogle Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
   PubMed Web of Science ®Google Scholar
• Kohara Y, Kubo K, Imamiya E, et al. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 1996;39:5228-35
   PubMed Web of Science ®Google Scholar
• Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011;336:801-8
   PubMed Web of Science ®Google Scholar
• French CJ, Zaman AK, Sobel BE. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011;58:143-8
   PubMed Web of Science ®Google Scholar
• Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007;20:579-86
   PubMed Web of Science ®Google Scholar
• Ye Y, Keyes KT, Zhang CF, et al. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther 2010;24:107-20
   PubMed Web of Science ®Google Scholar
• Zhao M, Li Y, Wang J, et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab 2011;13:1123-9
   PubMed Web of Science ®Google Scholar
• Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 2011;45:1506-15
   PubMed Web of Science ®Google Scholar
• Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
   PubMed Web of Science ®Google Scholar
• Edarbyclor, package insert. Takeda Pharmaceuticals, Deerfield IL, USA; 2012
   Google Scholar
• Mach RS, Veyrat R. Clinical experiences with some of the newer diuretics, especially chlorthalidone. Ann N Y Acad Sci 1960;88:841-63
   PubMed Web of Science ®Google Scholar
• Bakris BL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011;13:81-8
   PubMed Web of Science ®Google Scholar
• White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stage 1 and 2 hypertension. Hypertension 2011;57:413-20
   PubMed Web of Science ®Google Scholar
• Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011;13:467-72
   PubMed Web of Science ®Google Scholar
• Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012;35:552-8
   PubMed Web of Science ®Google Scholar
• Bonner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013;27:479-86
   PubMed Web of Science ®Google Scholar
• Weber MA, White WB, Sica D, et al. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit 2014;19:90-7
   PubMed Web of Science ®Google Scholar
• Takagi H, Mizuno Y, Niwa M, et al. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res 2014;37:432-7
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:3255-64
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1986;58:1-13
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 ½ years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990;82:1616-28
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Roush GC, Buddharaju V, Ernst ME. Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives? Curr Opin Cardiol 2013;28:426-32
   PubMed Web of Science ®Google Scholar
• Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8
   PubMed Web of Science ®Google Scholar
• Ernst ME, Carter BL, Zheng S, Grimm GH. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens 2010;23:440-6
   PubMed Web of Science ®Google Scholar
• Peterzan MA, Hardy R, Chaturvedi N, et al. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012;59:1104-9
   PubMed Web of Science ®Google Scholar
• Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011;57:689-94
   PubMed Web of Science ®Google Scholar
• Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med 2013;158:447-55
   PubMed Web of Science ®Google Scholar
• Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012;59:1110-17
   PubMed Web of Science ®Google Scholar
• Sica D, Bakris GL, White WB, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012;14:284-92
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012;125:1229. e1-1229.e10
   PubMed Web of Science ®Google Scholar
• Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension 2012;60:310-18
   PubMed Web of Science ®Google Scholar